Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative

Future Virology

Volumn 8, Issue 10, 2013, Pages 953-968

  Legand, Anaïs ^a   Briand, Sylvie ^a   Shindo, Nikki ^a   Brooks, W Abdullah ^b,c   De Jong, Menno D ^d   Farrar, Jeremy ^e   Aguilera, Ximena ^f   Hayden, Frederick G ^g  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^f UNIVERSIDAD DEL DESARROLLO   (Chile)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

antivirals; emerging respiratory viruses; influenza virus; pneumonia; public health policies; respiratory syncytial virus; respiratory viral infections; severe acute respiratory infection; vaccines; WHO research agenda

Indexed keywords

ALN RSV 01; ANTIVIRUS AGENT; ARBIDOL; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOOXYGENASE 2 INHIBITOR; DAS 181; FAVIPIRAVIR; GLITAZONE DERIVATIVE; GS 506; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; LANINAMIVIR; MDT 637; NITAZOXANIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; RADAVIRSEN; RETINOL; RI 001; RIBAVIRIN; SELENIUM; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D; ZANAMIVIR;

ACUTE OTITIS MEDIA; BRONCHIOLITIS OBLITERANS; EPIDEMIC; HEALTH CARE ORGANIZATION; HEMORRHAGIC FEVER; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MORBIDITY; MORTALITY; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RESPIRATORY VIRUS; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VIRUS INFECTION; VITAMIN SUPPLEMENTATION; WORLD HEALTH ORGANIZATION;

ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS;

EID: 84884249801     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.85     Document Type: Review

References (92)

1. Liu L, Johnson HL, Cousens S et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 379(9832), 2151-2161 (2012
2. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 377(9773), 1264-1275 (2011
3. Nair H, Simoes EA, Rudan I et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: A systematic analysis. Lancet 381(9875), 1380-1390 (2013
4. Gern JE. The ABCs of rhinoviruses, wheezing, and asthma. J. Virol. 84(15), 7418-7426 (2010
5. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10(8), 811-813 (2004
6. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ. Cardiovasc. Qual. Outcomes 2(2), 108-115 (2009
7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749-1759 (2005
8. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology 113(2), 98-107 (2009
9. van AL, van den Wijngaard C, van PW et al. Mortality attributable to 9 common infections: Significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J. Infect. Dis. 206(5), 628-639 (2012
10. Warren-Gash C, Bhaskaran K, Hayward A et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: A time series study in England and Wales and Hong Kong. J. Infect. Dis. 203(12), 1710-1718 (2011
11. Zhu T, Carcaillon L, Martinez I et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb. Haemost. 102(6), 1259-1264 (2009
12. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1), 71-79 (2012
13. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 25(27), 5086-5096 (2007
14. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med. 163(4), 487-494 (2003
15. Anderson LJ, Baric RS. Emerging human coronaviruses - disease potential and preparedness. N. Engl. J. Med. 367(19), 1850-1852 (2012
16. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368(20), 1888-1897 (2013
17. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N. Engl. J. Med. 368(20), 1862-1864 (2013
18. Zaki AM, van BS, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367(19), 1814-1820 (2012
19. Lee JW, McKibbin WJ. Estimating the global economic costs of SARS. In: Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary. Knobler S. Seale MAL (Eds). Institute of Medicine (US) Forum on Microbial Threats, National Academies Press, DC, USA (2004
20. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 36-44 (2012
21. Girard MP, Tam JS, Pervikov Y, Katz JM. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. Vaccine 31(37), 3766-3771 (2013
22. Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24(1), 44-46 (2005
23. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52(4), 447-456 (2011
24. Hung IF, To KK, Lee CK et al. Hyperimmune intravenous immunoglobulin treatment: A multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 144(2), 464-473 (2013
25. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: A meta-analysis of eleven randomized clinical trials. Clin. Infect. Dis. 53(3), 277-279 (2011
26. Chan MC, Lee N, Lui GC et al. Comparisons of oseltamivir-resistant (H275Y) and concurrent oseltamivir-susceptible seasonal influenza A(H1N1) virus infections in hospitalized adults, 2008-2009. Influenza Other Respi. Viruses 7(3), 235-239 (2013
27. Louie JK, Yang S, Acosta M et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin. Infect. Dis. 55(9), 1198-1204 (2012
28. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: A systematic review and meta-analysis in hospitalized patients. J. Infect. Dis. 207(4), 553-563 (2013
29. Yang SG, Cao B, Liang LR et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS ONE 7(1), e29652 (2012
30. Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respi. Viruses 7(Suppl. 1), 63-75 (2013
31. Hughes B, Hayden F, Perikov Y, Hombach J, Tam JS. Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses. World Health Organization, Geneva, 16-17 November 2011. Vaccine 30(47), 6612-6622 (2012
32. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003
33. Kouni S, Karakitsos P, Chranioti A, Theodoridou M, Chrousos G, Michos A. Evaluation of viral co-infections in hospitalized and non-hospitalized children with respiratory infections using microarrays. Clin. Microbiol. Infect. 19(8), 772-777 (2012
34. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J. Infect. Dis. 187(6), 1000-1009 (2003
35. Heinonen S, Silvennoinen H, Lehtinen P et al. Early oseltamivir treatment of influenza in children 1-3 years of age: A randomized controlled trial. Clin. Infect. Dis. 51(8), 887-894 (2010
36. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001
37. de Chassey B, Meyniel-Schicklin L, Aublin- Gex A, Andre P, Lotteau V. Genetic screens for the control of influenza virus replication: From meta-analysis to drug discovery. Mol. Biosyst. 8(4), 1297-1303 (2012
38. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol. Chem. 392(10), 837-847 (2011
39. Stertz S, Shaw ML. Uncovering the global host cell requirements for influenza virus replication via RNAi screening. Microbes. Infect. 13(5), 516-525 (2011
40. Smith SB, Dampier W, Tozeren A, Brown JR, Magid-Slav M. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS ONE 7(3), e33174 (2012
41. Jagger BW, Wise HM, Kash JC et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 337(6091), 199-204 (2012
42. Bezerra PG, Britto MC, Correia JB et al. Viral and atypical bacterial detection in acute respiratory infection in children under five years. PLoS ONE 6(4), e18928 (2011
43. Mermond S, Zurawski V, D'Ortenzio E et al. Lower respiratory infections among hospitalized children in New Caledonia: A pilot study for the Pneumonia Etiology Research for Child Health project. Clin. Infect. Dis. 54(Suppl. 2), S180-S189 (2012
44. Winther B, Hayden FG, Hendley JO. Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: Association with symptomatic illness and effect of season. J. Med. Virol. 78(5), 644-650 (2006
45. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12(10), 1203-1207 (2006
46. Everitt AR, Clare S, Pertel T et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484(7395), 519-523 (2012
47. Zhang YH, Zhao Y, Li N et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun. 4, 1418 (2013
48. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob. Agents Chemother. 56(1), 369-377 (2012
49. Yamada T, Yamada T, Morikawa M et al. Pandemic (H1N1) 2009 in pregnant Japanese women in Hokkaido. J. Obstet. Gynaecol. Res. 38(1), 130-136 (2012
50. Dubar G, Azria E, Tesniere A et al. French experience of 2009 A/H1N1v influenza in pregnant women. PLoS ONE 5(10), pii: E13112 (2010
51. Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir. Ther. 16(2), 237-247 (2011
52. Li IW, Hung IF, To KK et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 137(4), 759-768 (2010
53. Miller PE, Rambachan A, Hubbard RJ et al. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: An ecological study. PLoS ONE 7(9), e43491 (2012
54. Nukiwa N, Kamigaki T, Oshitani H. Fatal cases of pandemic (H1N1) 2009 influenza despite their early antiviral treatment in Japan. Clin. Infect. Dis. 51(8), 993-994 (2010
55. Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381(9885), 2273-2279 (2013
56. Geevarghese B, Simoes EA. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir. Ther. 17(1 Pt B), 201-211 (2012
57. DeVincenzo JP. The promise, pitfalls and progress of RNA-interference- based antiviral therapy for respiratory viruses. Antivir. Ther. 17(1 Pt B), 213-225 (2012
58. Chen YB, Driscoll JP, McAfee SL et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin. Infect. Dis. 53(7), e77-e80 (2011
59. Florescu DF, Pergam SA, Neely MN et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol. Blood Marrow Transplant. 18(5), 731-738 (2012
60. Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev. Med. Virol. 21(6), 358-369 (2011
61. Agrati C, Gioia C, Lalle E et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J. Infect. Dis. 202(5), 681-689 (2010
62. Camargo CA Jr, Ganmaa D, Frazier AL et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 130(3), e561-e567 (2012
63. Murdoch DR, Slow S, Chambers ST et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: The VIDARIS randomized controlled trial. JAMA 308(13), 1333-1339 (2012
64. Roth DE, Caulfield LE, Ezzati M, Black RE. Acute lower respiratory infections in childhood: Opportunities for reducing the global burden through nutritional interventions. Bull. World Health Organ. 86(5), 356-364 (2008
65. Scott JA, Brooks WA, Peiris JS, Holtzman D, Mulholland EK. Pneumonia research to reduce childhood mortality in the developing world. J. Clin. Invest 118(4), 1291-1300 (2008
66. Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst. Rev. 2, CD001364 (2011
67. Popova M, Molimard P, Courau S et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J. Appl. Microbiol. 113(6), 1305-1318 (2012
68. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. doi:10.1016/j. antiviral.2013.06.018 (2013) (Epub ahead of print
69. Shillcutt S, Morel C, Goodman C et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull. World Health Organ. 86(2), 101-110 (2008
70. Thiam S, Thior M, Faye B et al. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. PLoS ONE 6(4), e18419 (2011
71. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin. Infect. Dis. 52(Suppl. 4), S346-S350 (2011
72. Zimmerman O, Rogowski O, Aviram G et al. C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A virus infection. BMC Infect. Dis. 10, 288 (2010
73. Vernet G, Saha S, Satzke C et al. Laboratory-based diagnosis of pneumococcal pneumonia: State of the art and unmet needs. Clin. Microbiol. Infect. 17(Suppl. 3), 1-13 (2011
74. Belle J, Cohen H, Shindo N et al. Influenza preparedness in low-resource settings: A look at oxygen delivery in 12 African countries. J. Infect. Dev. Ctries 4(7), 419-424 (2010
75. Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: A population-based cohort study. Pediatrics 130(4), e794-e803 (2012
76. Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early-life body mass. Int. J. Obes. (Lond.) 37(1), 16-23 (2013
77. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am. J. Respir. Crit. Care Med. 185(1), 12-23 (2012
78. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 183(9), 1200-1206 (2011
79. Kim SH, Hong SB, Yun SC et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: Analytic strategy using propensity scores. Am. J. Respir. Crit. Care Med. 183(9), 1207-1214 (2011
80. Martin-Loeches I, Lisboa T, Rhodes A et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 37(2), 272-283 (2011
81. Ranzani OT, Ferrer M, Esperatti M et al. Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. Crit. Care Med. 40(9), 2552-2561 (2012
82. Eyers S, Weatherall M, Shirtcliffe P, Perrin K, Beasley R. The effect on mortality of antipyretics in the treatment of influenza infection: Systematic review and meta-analysis. J. R. Soc. Med. 103(10), 403-411 (2010
83. Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics 127(3), 580-587 (2011
84. InFACT: A global critical care research response to H1N1. Lancet 375(9708), 11-13 (2010
85. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 41(2), 580-637 (2013
86. Brooks WA. A four-stage strategy to reduce childhood pneumonia-related mortality by 2015 and beyond. Vaccine 27(5), 619-623 (2009
87. Aiello AE, Coulborn RM, Aragon TJ et al. Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research. Am. J. Infect. Control 38(4), 251-258 (2010
88. Copeland DL, Basurto-Davila R, Chung W et al. Effectiveness of a school district closure for pandemic influenza A (H1N1) on acute respiratory illnesses in the community: A natural experiment. Clin. Infect. Dis. 56(4), 509-516 (2013
89. Nair H, Brooks WA, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. Lancet 378(9807), 1917-1930 (2011
90. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010
91. O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 374(9693), 893-902 (2009
92. Watt JP, Wolfson LJ, O'Brien KL et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates. Lancet 374(9693), 903-911 (2009